Titre : Hyperplasie lymphoïde angiofolliculaire

Hyperplasie lymphoïde angiofolliculaire : Questions médicales fréquentes

Termes MeSH sélectionnés :

Pilot Projects
{ "@context": "https://schema.org", "@graph": [ { "@type": "MedicalWebPage", "name": "Hyperplasie lymphoïde angiofolliculaire : Questions médicales les plus fréquentes", "headline": "Hyperplasie lymphoïde angiofolliculaire : Comprendre les symptômes, diagnostics et traitements", "description": "Guide complet et accessible sur les Hyperplasie lymphoïde angiofolliculaire : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.", "datePublished": "2024-01-26", "dateModified": "2025-04-20", "inLanguage": "fr", "medicalAudience": [ { "@type": "MedicalAudience", "name": "Grand public", "audienceType": "Patient", "healthCondition": { "@type": "MedicalCondition", "name": "Hyperplasie lymphoïde angiofolliculaire" }, "suggestedMinAge": 18, "suggestedGender": "unisex" }, { "@type": "MedicalAudience", "name": "Médecins", "audienceType": "Physician", "geographicArea": { "@type": "AdministrativeArea", "name": "France" } }, { "@type": "MedicalAudience", "name": "Chercheurs", "audienceType": "Researcher", "geographicArea": { "@type": "AdministrativeArea", "name": "International" } } ], "reviewedBy": { "@type": "Person", "name": "Dr Olivier Menir", "jobTitle": "Expert en Médecine", "description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale", "url": "/static/pages/docteur-olivier-menir.html", "alumniOf": { "@type": "EducationalOrganization", "name": "Université Paris Descartes" } }, "isPartOf": { "@type": "MedicalWebPage", "name": "Syndromes lymphoprolifératifs", "url": "https://questionsmedicales.fr/mesh/D008232", "about": { "@type": "MedicalCondition", "name": "Syndromes lymphoprolifératifs", "code": { "@type": "MedicalCode", "code": "D008232", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "C20.683.515" } } }, "about": { "@type": "MedicalCondition", "name": "Hyperplasie lymphoïde angiofolliculaire", "alternateName": "Castleman Disease", "code": { "@type": "MedicalCode", "code": "D005871", "codingSystem": "MeSH" } }, "author": [ { "@type": "Person", "name": "David C Fajgenbaum", "url": "https://questionsmedicales.fr/author/David%20C%20Fajgenbaum", "affiliation": { "@type": "Organization", "name": "Center for Cytokine Storm Treatment & Laboratory, University of Pennsylvania, Philadelphia, PA, USA." } }, { "@type": "Person", "name": "Angela Dispenzieri", "url": "https://questionsmedicales.fr/author/Angela%20Dispenzieri", "affiliation": { "@type": "Organization", "name": "Division of Hematology, Mayo Clinic, Rochester, MN; and." } }, { "@type": "Person", "name": "Kazue Takai", "url": "https://questionsmedicales.fr/author/Kazue%20Takai", "affiliation": { "@type": "Organization", "name": "Department of Hematology, Niigata City General Hospital, Niigata, Japan." } }, { "@type": "Person", "name": "Eric Oksenhendler", "url": "https://questionsmedicales.fr/author/Eric%20Oksenhendler", "affiliation": { "@type": "Organization", "name": "Département d'immunologie Clinique, Hôpital Saint-Louis, Université de Paris, Paris, France." } }, { "@type": "Person", "name": "Wei Wang", "url": "https://questionsmedicales.fr/author/Wei%20Wang", "affiliation": { "@type": "Organization", "name": "Department of Hematopathology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA." } } ], "citation": [ { "@type": "ScholarlyArticle", "name": "Implementing Digital Cognitive-Behavioral Therapy for Major Depressive Disorder in Routine Psychiatric Appointments: A Pilot Project in a Rural Population.", "datePublished": "2023-05-03", "url": "https://questionsmedicales.fr/article/37134285", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.3928/02793695-20230424-01" } }, { "@type": "ScholarlyArticle", "name": "An Innovative Approach to Delivering a Family-Based Intervention to Address Parental Alcohol Misuse: Qualitative Findings from a Pilot Project.", "datePublished": "2022-07-01", "url": "https://questionsmedicales.fr/article/35805744", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.3390/ijerph19138086" } }, { "@type": "ScholarlyArticle", "name": "Shared learning experiences: Pilot study of an online exchange project between pharmacy students in South Africa and the United States.", "datePublished": "2023-07-26", "url": "https://questionsmedicales.fr/article/37507312", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1016/j.cptl.2023.06.021" } }, { "@type": "ScholarlyArticle", "name": "An Automated Text Messaging Intervention to Reduce Substance Use Self-Stigma (Project RESTART): Protocol for a Feasibility and Acceptability Pilot Study.", "datePublished": "2024-08-09", "url": "https://questionsmedicales.fr/article/39121478", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.2196/59224" } }, { "@type": "ScholarlyArticle", "name": "Frequency of actionable secondary findings in 7472 Korean genomes derived from the National Project of Bio Big Data pilot study.", "datePublished": "2023-09-20", "url": "https://questionsmedicales.fr/article/37728764", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1007/s00439-023-02592-8" } } ], "breadcrumb": { "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "questionsmedicales.fr", "item": "https://questionsmedicales.fr" }, { "@type": "ListItem", "position": 2, "name": "Maladies du système immunitaire", "item": "https://questionsmedicales.fr/mesh/D007154" }, { "@type": "ListItem", "position": 3, "name": "Syndromes immunoprolifératifs", "item": "https://questionsmedicales.fr/mesh/D007160" }, { "@type": "ListItem", "position": 4, "name": "Syndromes lymphoprolifératifs", "item": "https://questionsmedicales.fr/mesh/D008232" }, { "@type": "ListItem", "position": 5, "name": "Hyperplasie lymphoïde angiofolliculaire", "item": "https://questionsmedicales.fr/mesh/D005871" } ] } }, { "@type": "MedicalWebPage", "name": "Article complet : Hyperplasie lymphoïde angiofolliculaire - Questions et réponses", "headline": "Questions et réponses médicales fréquentes sur Hyperplasie lymphoïde angiofolliculaire", "description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.", "datePublished": "2025-05-17", "inLanguage": "fr", "hasPart": [ { "@type": "MedicalWebPage", "name": "Diagnostic", "headline": "Diagnostic sur Hyperplasie lymphoïde angiofolliculaire", "description": "Comment diagnostiquer la maladie de Castleman ?\nQuels tests sont utilisés pour confirmer le diagnostic ?\nQuels signes cliniques indiquent une hyperplasie lymphoïde ?\nLa maladie de Castleman est-elle toujours symptomatique ?\nQuel rôle joue l'imagerie dans le diagnostic ?", "url": "https://questionsmedicales.fr/mesh/D005871?mesh_terms=Pilot+Projects&page=6#section-diagnostic" }, { "@type": "MedicalWebPage", "name": "Symptômes", "headline": "Symptômes sur Hyperplasie lymphoïde angiofolliculaire", "description": "Quels sont les symptômes courants de la maladie de Castleman ?\nLa fatigue est-elle un symptôme de cette maladie ?\nPeut-on avoir des sueurs nocturnes avec cette maladie ?\nLes symptômes varient-ils d'un patient à l'autre ?\nY a-t-il des symptômes spécifiques à la forme multicentrique ?", "url": "https://questionsmedicales.fr/mesh/D005871?mesh_terms=Pilot+Projects&page=6#section-symptômes" }, { "@type": "MedicalWebPage", "name": "Prévention", "headline": "Prévention sur Hyperplasie lymphoïde angiofolliculaire", "description": "Peut-on prévenir la maladie de Castleman ?\nY a-t-il des facteurs de risque identifiés ?\nLes habitudes de vie influencent-elles le risque ?\nLes vaccinations peuvent-elles aider ?\nLe dépistage précoce est-il utile ?", "url": "https://questionsmedicales.fr/mesh/D005871?mesh_terms=Pilot+Projects&page=6#section-prévention" }, { "@type": "MedicalWebPage", "name": "Traitements", "headline": "Traitements sur Hyperplasie lymphoïde angiofolliculaire", "description": "Quels traitements sont disponibles pour la maladie de Castleman ?\nLa radiothérapie est-elle utilisée dans le traitement ?\nLes corticostéroïdes sont-ils efficaces ?\nQuel est le rôle des thérapies ciblées ?\nLa surveillance est-elle nécessaire après le traitement ?", "url": "https://questionsmedicales.fr/mesh/D005871?mesh_terms=Pilot+Projects&page=6#section-traitements" }, { "@type": "MedicalWebPage", "name": "Complications", "headline": "Complications sur Hyperplasie lymphoïde angiofolliculaire", "description": "Quelles complications peuvent survenir avec Castleman ?\nLa maladie de Castleman peut-elle entraîner des infections ?\nY a-t-il un risque de cancer associé ?\nComment gérer les complications ?\nLes complications affectent-elles le pronostic ?", "url": "https://questionsmedicales.fr/mesh/D005871?mesh_terms=Pilot+Projects&page=6#section-complications" }, { "@type": "MedicalWebPage", "name": "Facteurs de risque", "headline": "Facteurs de risque sur Hyperplasie lymphoïde angiofolliculaire", "description": "Quels sont les principaux facteurs de risque ?\nL'âge influence-t-il le risque de Castleman ?\nLe sexe joue-t-il un rôle dans le risque ?\nLes antécédents familiaux sont-ils un facteur ?\nLe mode de vie affecte-t-il le risque ?", "url": "https://questionsmedicales.fr/mesh/D005871?mesh_terms=Pilot+Projects&page=6#section-facteurs de risque" } ] }, { "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "Comment diagnostiquer la maladie de Castleman ?", "position": 1, "acceptedAnswer": { "@type": "Answer", "text": "Le diagnostic repose sur l'examen clinique, l'imagerie et la biopsie des ganglions lymphatiques." } }, { "@type": "Question", "name": "Quels tests sont utilisés pour confirmer le diagnostic ?", "position": 2, "acceptedAnswer": { "@type": "Answer", "text": "Des tests sanguins, des échographies et des IRM peuvent être utilisés pour évaluer l'étendue de la maladie." } }, { "@type": "Question", "name": "Quels signes cliniques indiquent une hyperplasie lymphoïde ?", "position": 3, "acceptedAnswer": { "@type": "Answer", "text": "Des ganglions lymphatiques enflés, de la fièvre et des sueurs nocturnes peuvent indiquer la maladie." } }, { "@type": "Question", "name": "La maladie de Castleman est-elle toujours symptomatique ?", "position": 4, "acceptedAnswer": { "@type": "Answer", "text": "Non, certains patients peuvent être asymptomatiques, rendant le diagnostic plus difficile." } }, { "@type": "Question", "name": "Quel rôle joue l'imagerie dans le diagnostic ?", "position": 5, "acceptedAnswer": { "@type": "Answer", "text": "L'imagerie aide à visualiser les ganglions lymphatiques et à évaluer leur taille et leur nombre." } }, { "@type": "Question", "name": "Quels sont les symptômes courants de la maladie de Castleman ?", "position": 6, "acceptedAnswer": { "@type": "Answer", "text": "Les symptômes incluent des ganglions lymphatiques enflés, de la fièvre, et des douleurs abdominales." } }, { "@type": "Question", "name": "La fatigue est-elle un symptôme de cette maladie ?", "position": 7, "acceptedAnswer": { "@type": "Answer", "text": "Oui, la fatigue est fréquente et peut résulter de l'inflammation et de l'anémie associées." } }, { "@type": "Question", "name": "Peut-on avoir des sueurs nocturnes avec cette maladie ?", "position": 8, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les sueurs nocturnes sont un symptôme courant chez les patients atteints de Castleman." } }, { "@type": "Question", "name": "Les symptômes varient-ils d'un patient à l'autre ?", "position": 9, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les symptômes peuvent varier en fonction du type et de la gravité de la maladie." } }, { "@type": "Question", "name": "Y a-t-il des symptômes spécifiques à la forme multicentrique ?", "position": 10, "acceptedAnswer": { "@type": "Answer", "text": "Oui, la forme multicentrique peut entraîner des symptômes systémiques plus prononcés." } }, { "@type": "Question", "name": "Peut-on prévenir la maladie de Castleman ?", "position": 11, "acceptedAnswer": { "@type": "Answer", "text": "Il n'existe pas de méthode de prévention connue pour la maladie de Castleman." } }, { "@type": "Question", "name": "Y a-t-il des facteurs de risque identifiés ?", "position": 12, "acceptedAnswer": { "@type": "Answer", "text": "Des facteurs comme l'infection par le VIH et certaines maladies auto-immunes peuvent augmenter le risque." } }, { "@type": "Question", "name": "Les habitudes de vie influencent-elles le risque ?", "position": 13, "acceptedAnswer": { "@type": "Answer", "text": "Des habitudes de vie saines peuvent aider à réduire le risque de maladies en général." } }, { "@type": "Question", "name": "Les vaccinations peuvent-elles aider ?", "position": 14, "acceptedAnswer": { "@type": "Answer", "text": "Bien que les vaccinations ne préviennent pas Castleman, elles protègent contre d'autres infections." } }, { "@type": "Question", "name": "Le dépistage précoce est-il utile ?", "position": 15, "acceptedAnswer": { "@type": "Answer", "text": "Le dépistage précoce n'est pas standardisé pour Castleman, mais un suivi médical régulier est conseillé." } }, { "@type": "Question", "name": "Quels traitements sont disponibles pour la maladie de Castleman ?", "position": 16, "acceptedAnswer": { "@type": "Answer", "text": "Les traitements incluent la chirurgie, la chimiothérapie et les thérapies ciblées." } }, { "@type": "Question", "name": "La radiothérapie est-elle utilisée dans le traitement ?", "position": 17, "acceptedAnswer": { "@type": "Answer", "text": "Oui, la radiothérapie peut être utilisée pour traiter les formes localisées de la maladie." } }, { "@type": "Question", "name": "Les corticostéroïdes sont-ils efficaces ?", "position": 18, "acceptedAnswer": { "@type": "Answer", "text": "Les corticostéroïdes peuvent réduire l'inflammation et soulager certains symptômes." } }, { "@type": "Question", "name": "Quel est le rôle des thérapies ciblées ?", "position": 19, "acceptedAnswer": { "@type": "Answer", "text": "Les thérapies ciblées visent des molécules spécifiques pour inhiber la croissance tumorale." } }, { "@type": "Question", "name": "La surveillance est-elle nécessaire après le traitement ?", "position": 20, "acceptedAnswer": { "@type": "Answer", "text": "Oui, un suivi régulier est essentiel pour détecter toute récidive ou complication." } }, { "@type": "Question", "name": "Quelles complications peuvent survenir avec Castleman ?", "position": 21, "acceptedAnswer": { "@type": "Answer", "text": "Les complications incluent l'insuffisance organique, l'infection et le développement de lymphomes." } }, { "@type": "Question", "name": "La maladie de Castleman peut-elle entraîner des infections ?", "position": 22, "acceptedAnswer": { "@type": "Answer", "text": "Oui, l'immunosuppression liée à la maladie peut augmenter le risque d'infections." } }, { "@type": "Question", "name": "Y a-t-il un risque de cancer associé ?", "position": 23, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les patients peuvent avoir un risque accru de développer des lymphomes ou d'autres cancers." } }, { "@type": "Question", "name": "Comment gérer les complications ?", "position": 24, "acceptedAnswer": { "@type": "Answer", "text": "La gestion des complications nécessite une approche multidisciplinaire et un suivi régulier." } }, { "@type": "Question", "name": "Les complications affectent-elles le pronostic ?", "position": 25, "acceptedAnswer": { "@type": "Answer", "text": "Oui, la présence de complications peut aggraver le pronostic et compliquer le traitement." } }, { "@type": "Question", "name": "Quels sont les principaux facteurs de risque ?", "position": 26, "acceptedAnswer": { "@type": "Answer", "text": "Les infections virales, notamment par le VIH, et certaines maladies auto-immunes sont des facteurs de risque." } }, { "@type": "Question", "name": "L'âge influence-t-il le risque de Castleman ?", "position": 27, "acceptedAnswer": { "@type": "Answer", "text": "Oui, la maladie peut survenir à tout âge, mais elle est plus fréquente chez les jeunes adultes." } }, { "@type": "Question", "name": "Le sexe joue-t-il un rôle dans le risque ?", "position": 28, "acceptedAnswer": { "@type": "Answer", "text": "Des études montrent que les hommes peuvent être plus susceptibles de développer la maladie." } }, { "@type": "Question", "name": "Les antécédents familiaux sont-ils un facteur ?", "position": 29, "acceptedAnswer": { "@type": "Answer", "text": "Il n'y a pas de preuve solide que les antécédents familiaux augmentent le risque de Castleman." } }, { "@type": "Question", "name": "Le mode de vie affecte-t-il le risque ?", "position": 30, "acceptedAnswer": { "@type": "Answer", "text": "Un mode de vie sain peut réduire le risque de nombreuses maladies, mais son impact sur Castleman est incertain." } } ] } ] }

Sources (10000 au total)

Implementing Digital Cognitive-Behavioral Therapy for Major Depressive Disorder in Routine Psychiatric Appointments: A Pilot Project in a Rural Population.

Psychotherapy is well-established as an effective treatment for major depressive disorder (MDD). However, many individuals with MDD in rural areas of the United States do not have access to psychother...

Shared learning experiences: Pilot study of an online exchange project between pharmacy students in South Africa and the United States.

Internationalisation enhances students' understanding of social, cultural, and ethical differences, preparing them to be global-minded, socially accountable healthcare practitioners. Traditionally, in... The virtual peer exchange project allowed students in SA and the US to establish connections within the global pharmacy community and compare healthcare, pharmacy education, and pharmacy practice betw... Twenty-one students participated in the pilot project that met some of the intentions and goals of internationalisation via a virtual platform. Two over-arching themes of Practice of Pharmacy and Phar... This project was a unique way to conduct exchange programmes via a virtual platform, and bypassed challenges of traditional exchange programmes. Through technology, more students in diverse geographic...

An Automated Text Messaging Intervention to Reduce Substance Use Self-Stigma (Project RESTART): Protocol for a Feasibility and Acceptability Pilot Study.

Stigma is a barrier to treatment and harm reduction seeking in people who use drugs. Most stigma reduction interventions offer psychotherapy or psychoeducation in group-based clinical settings, failin... This paper presents the protocol for a study that aims to determine the feasibility, acceptability, and preliminary effectiveness of a 4-week automated SMS text message intervention to increase stigma... We designed a novel automated SMS text message intervention to address the four personal-level constructs of stigma resistance: (1) not believing stigma and catching and challenging stigmatizing thoug... This pilot study was funded by the National Institute on Drug Abuse in April 2023 and received regulatory approval in January 2024 by the University of North Carolina-Chapel Hill Institutional Review ... To the best of our knowledge, this is the first study to address substance use stigma via a self-help SMS text messaging program. Results will add to the nascent literature on stigma reduction in peop... ClinicalTrials.gov NCT06281548; https://clinicaltrials.gov/ct2/show/NCT06281548.... DERR1-10.2196/59224....

Project Inspire pilot study: A hospital-led comprehensive intervention reduces gun violence among juveniles delinquent of gun crimes.

Gun violence disproportionately affects young Black men, but the impact extends to families and communities. Those at highest risk are teens delinquent of gun crimes. While there is no nationally acce... Led by a level 1 trauma center, key community stakeholders including the juvenile court, city, and city police department joined forces to create a community-wide program aimed at curbing gun violence... Project Inspire has hosted two classes in 2018 and 2019, graduating nine participants aged 14 to 17 years. Sixty-seven percent were Black. All were males. At 1 year, none of the graduates reoffended. ... Project Inspire is a hospital-led initiative that effectively reduces recidivism among juveniles delinquent of gun crimes. This sets the framework for trauma centers nationwide to lead in establishing... Prognostic and Epidemiological; Level V....

The "Young Athlete Body Project"-A pilot study evaluating the acceptability of and results from an eating disorder prevention program for adolescent athletes.

The high frequency of eating disorders (EDs) in sports speaks of a need for early-stage preventive measures.... This study evaluated the acceptability of an age, sex, and sports adapted version of the "Body Project" and changes in mental health symptoms.... This noncontrolled pilot study included a class of athletes from 18 sports (N = 73, 13-14 years) at a sport-specialized junior high school in six small-group workshops. We interviewed 34 athletes on p... Athletes found the program acceptable and beneficial, but some missed physically oriented activities or did not identify with the focus, particularly boys. There were acceptable levels in mental healt... Athletes experienced benefits from the Young Athlete Body Project. Seeing stabilization in outcomes may mean a dampening of the otherwise expected worsening in body appreciation and ED symptoms over t... Adolescent athletes are at risk for developing EDs. Due to lack of prevention programs for this group, we adapted and evaluated a well-documented effective program, the Body Project, to fit male and f...

Evaluation of power wheelchair driving performance in simulator compared to driving in real-life situations: the SIMADAPT (simulator ADAPT) project-a pilot study.

The objective of this study was to evaluate users' driving performances with a Power Wheelchair (PWC) driving simulator in comparison to the same driving task in real conditions with a standard power ... Three driving circuits of progressive difficulty levels (C1, C2, C3) that were elaborated to assess the driving performances with PWC in indoor situations, were used in this study. These circuits have... Thirty-one participants with neurological disorders and expert wheelchair drivers were included in the study. The driving performances between VR and R conditions were statistically different for the ... Driving performances were statistically different in the most complicated circuit C3 with an increased number of collisions in VR, but were not statistically different for the two easiest circuits C1 ...

Impact of the Momentum pilot project on male involvement in maternal health and newborn care in Kinshasa, Democratic Republic of the Congo: a quasi-experimental study.

The World Health Organization recommends that programs that seek to improve maternal and newborn health outcomes actively involve men during pregnancy, childbirth, and postpartum. However, there is li... The study used a quasi-experimental design with three intervention and three comparison health zones. Baseline data were collected in 2018 and endline data in 2020. Exploratory factor analysis was use... Intervention health zones were associated with an 18.1 percentage point (95% CI [(10.6, 25.6]) increase in knowledge of three or more obstetric danger signs and a 13.9 percentage point (95% CI [6.3, 2... The study demonstrated the effectiveness of Momentum on male involvement in maternal health and newborn care....